2024
Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation
Trogdon M, Abbott K, Arang N, Lande K, Kaur N, Tong M, Bakhoum M, Gutkind J, Stites E. Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation. Npj Systems Biology And Applications 2024, 10: 75. PMID: 39013872, PMCID: PMC11252164, DOI: 10.1038/s41540-024-00400-1.Peer-Reviewed Original ResearchConceptsSignaling networksMathematical models of biochemical reaction networksModels of biochemical reaction networksG-proteinCell signaling networksDisease-causing mutationsComputational systems biologyBiochemical reaction networksDownstream pathway activationSignaling phenotypeSystems biologyBioinformatics analysisGPCR signalingMutationsCo-occurring mutationsOncogenic mutationsPathway activationDiscovery toolPathwayReaction networkSignalCYSLTR2 mutationsDiscoveryPhenotypeMutually-exclusive
2023
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
Coleman N, Marcelo K, Hopkins J, Khan N, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, Myers J, Heymach J, Albacker L, Hong D, Gillison M, Le X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200211. PMID: 36603172, PMCID: PMC9928766, DOI: 10.1200/po.22.00211.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaMD Anderson Cancer CenterSquamous cell carcinomaAnderson Cancer CenterCo-occurring mutationsClinical courseSurvival outcomesCancer CenterCell carcinomaShorter disease-free survivalPoor clinic outcomePrimary definitive treatmentTherapeutic combination strategiesDisease-free survivalPoor clinical outcomePatient demographic informationImproved OSDefinitive treatmentMedian ageOverall survivalFoundation MedicineMale patientsClinical outcomesClinic outcomesTreatment response
2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
Ball S, Aguirre L, Jain A, Ali N, Tinsley S, Chan O, Kuykendall A, Sweet K, Lancet J, Sallman D, Hussaini M, Padron E, Komrokji R. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leukemia Research 2022, 124: 106999. PMID: 36542963, DOI: 10.1016/j.leukres.2022.106999.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMedian OSEZH2 mutationsAssociated with inferior median OSAssociated with significantly worse OSMedian OS of patientsSingle-center retrospective studyInferior median OSIPSS-R categoryOS of patientsChromosome 7 abnormalitiesMoffitt Cancer CenterCo-occurring mutationsDeterminants of outcomeEZH2-mutationHypomethylating agentsRUNX1 mutationsMyeloid neoplasmsClinical characteristicsRetrospective studyClinical trialsCancer CenterPatientsImprove outcomesASXL1
2015
Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative
Tarlock K, Hansen M, Hylkema T, Ries R, Farrar J, Auvil J, Gerhard D, Smith M, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Mungall K, Ma Y, Zong S, Long W, Boggon T, Alonzo T, Kolb E, Gamis A, Meshinchi S. Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood 2015, 126: 87. DOI: 10.1182/blood.v126.23.87.87.Peer-Reviewed Original ResearchFLT3/ITDChildren's Oncology GroupFLT3 mutationsOncology GroupPediatric cohortPediatric AMLFLT3 geneActivating mutationsTyrosine kinase domainAcute myeloid leukemiaDe novo resistanceInternal tandem duplicationJuxtamembrane domainCommon activating mutationsCo-occurring mutationsTargeted exome captureResistance conferring mutationsCOG trialsChildhood AMLUnnecessary toxicityInhibitor exposureFLT3 inhibitionNovo resistanceAdult studiesExcessive activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply